Metropolitan Life Insurance CO Novo Cure LTD Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jun 21, 2023	BUY	$75.08 - $121.99 $511,294 - $830,751	6,810 New	6,810 $511 Million
Q3 2021 Jun 21, 2023	BUY	$116.17 - $194.55 $797,274 - $1.34 Million	6,863 New	6,863 $797 Million
Q1 2021 Jun 26, 2023	BUY	$124.11 - $190.17 $908,733 - $1.39 Million	7,322 New	7,322 $968 Million
Q4 2020 Jun 22, 2023	BUY	$112.16 - $174.14 $858,248 - $1.33 Million	7,652 New	7,652 $1.32 Billion
Q3 2020 Jun 26, 2023	BUY	$58.05 - $111.31 $446,810 - $856,753	7,697 New	7,697 $857 Million
Q2 2020 Jun 26, 2023	BUY	$57.2 - $74.41 $451,651 - $587,541	7,896 New	7,896 $468 Million
Q1 2020 Jul 12, 2023	BUY	$57.05 - $95.75 $1.49 Million - $2.51 Million	26,184 New	26,184 $1.76 Billion
Q4 2019 Jul 12, 2023	BUY	$68.3 - $93.8 $1.83 Million - $2.51 Million	26,752 New	26,752 $2.25 Billion
Q3 2019 Jul 12, 2023	BUY	$61.86 - $97.8 $1.7 Million - $2.69 Million	27,490 New	27,490 $2.06 Billion
Q2 2019 Jul 12, 2023	BUY	$42.22 - $63.23 $990,016 - $1.48 Million	23,449 New	23,449 $1.48 Billion
Q1 2019 Jul 13, 2023	BUY	$31.96 - $56.12 $749,430 - $1.32 Million	23,449 New	23,449 $1.13 Billion

262

76.9M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.75B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.